UroGen Pharma Reports Strong Q1 2026 Earnings with Significant ZUSDURI Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy URGN?
Source: seekingalpha
- ZUSDURI Revenue Surge: UroGen Pharma reported $29.2 million in ZUSDURI revenue for Q1 2026, representing over 100% quarter-over-quarter growth, indicating a significant increase in market acceptance and suggesting substantial future sales potential.
- Increase in Prescribers: By the end of Q1, UroGen had 256 unique prescribers, up from 102 at year-end, with repeat prescribers rising from 32 to 103, demonstrating accelerated market penetration and growing physician engagement.
- Improved Financial Performance: The company achieved total revenue of $51 million in Q1, a substantial increase from $20.3 million in the same quarter of 2025, although it reported a net loss of $23.6 million, which is an improvement from a loss of $43.8 million a year earlier, indicating a gradual financial recovery.
- Optimistic Future Outlook: Management expects continued strong growth throughout 2026, although formal sales guidance for ZUSDURI is not provided; however, net product revenues for JELMYTO are projected to be between $97 million and $101 million, reflecting confidence in the product line.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy URGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on URGN
Wall Street analysts forecast URGN stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.250
Low
31.00
Averages
40.25
High
55.00
Current: 26.250
Low
31.00
Averages
40.25
High
55.00
About URGN
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UroGen Pharma Reports Strong Q1 2026 Earnings with Significant ZUSDURI Growth
- ZUSDURI Revenue Surge: UroGen Pharma reported $29.2 million in ZUSDURI revenue for Q1 2026, representing over 100% quarter-over-quarter growth, indicating a significant increase in market acceptance and suggesting substantial future sales potential.
- Increase in Prescribers: By the end of Q1, UroGen had 256 unique prescribers, up from 102 at year-end, with repeat prescribers rising from 32 to 103, demonstrating accelerated market penetration and growing physician engagement.
- Improved Financial Performance: The company achieved total revenue of $51 million in Q1, a substantial increase from $20.3 million in the same quarter of 2025, although it reported a net loss of $23.6 million, which is an improvement from a loss of $43.8 million a year earlier, indicating a gradual financial recovery.
- Optimistic Future Outlook: Management expects continued strong growth throughout 2026, although formal sales guidance for ZUSDURI is not provided; however, net product revenues for JELMYTO are projected to be between $97 million and $101 million, reflecting confidence in the product line.
See More
UroGen Pharma Q1 Earnings Beat Expectations
- Earnings Highlights: UroGen Pharma reported a Q1 GAAP EPS of -$0.47, beating expectations by $0.01, indicating a slight improvement in financial performance despite ongoing losses.
- Revenue Surge: The company achieved Q1 revenue of $51 million, reflecting a remarkable 151.2% year-over-year increase, surpassing estimates by $6.18 million, which underscores strong market demand for its products.
- Future Guidance: UroGen expects net product revenue for JELMYTO in 2026 to range between $97 million and $101 million, implying a year-over-year growth rate of approximately 3% to 7% over the $94 million reported in 2025, indicating a stable market outlook.
- Expense Projections: The company anticipates full-year 2026 operating expenses to be between $240 million and $250 million, including non-cash share-based compensation expenses of $20 million to $24 million, highlighting the cost pressures associated with business expansion.
See More
UroGen Pharma to Announce Q1 Earnings on May 6
- Earnings Announcement Timing: UroGen Pharma is set to release its Q1 2023 earnings report on May 6 before the market opens, with investors keenly awaiting performance insights to gauge future growth potential.
- Profit and Revenue Expectations: The consensus EPS estimate stands at -$0.48, reflecting a 47.8% year-over-year increase, while the revenue estimate is $44.82 million, indicating a substantial 120.8% year-over-year growth, showcasing strong momentum in revenue generation.
- Performance Beat Record: Over the past year, UroGen has only beaten EPS and revenue estimates 25% of the time, indicating significant volatility in its performance, which investors should closely monitor in upcoming results.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen three upward revisions and four downward adjustments, while revenue estimates have experienced two upward and five downward revisions, highlighting market uncertainty and differing expectations regarding the company's future performance.
See More
UroGen Pharma Reports 2025 Financial Highlights
- Significant Revenue Growth: UroGen Pharma reported fourth-quarter 2025 revenue of $37.8 million, a 53.3% increase from $24.6 million in the same quarter of 2024, indicating strong market demand following the launch of new products and enhancing future revenue expectations.
- Narrowed Net Loss: The net loss for the fourth quarter of 2025 was $26.4 million, or $0.54 per share, significantly improved from a net loss of $37.5 million, or $0.80 per share in the same quarter of 2024, reflecting effective cost control and revenue growth.
- Successful Launch of ZUSDURI: ZUSDURI, the first FDA-approved therapy for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, generated $15.8 million in net sales during 2025, with expectations for broader patient access supported by a permanent J Code effective January 1, 2026.
- Refinancing Agreement Restructured: UroGen secured up to $250 million in senior secured debt through a refinancing agreement with Pharmakon Advisors, with the first tranche of $200 million used to refinance an existing loan, alleviating financial pressure and providing funding for future R&D.
See More
UroGen Pharma Q4 2025 Earnings Call Highlights
- ZUSDURI Commercial Launch: UroGen Pharma's ZUSDURI generated $15.8 million in revenue for 2025, reflecting a strong market entry in non-muscle invasive bladder cancer, with potential peak revenue exceeding $1 billion anticipated in the future.
- Enhanced Financial Flexibility: The company secured a new $250 million loan agreement with Pharmakon Advisors, significantly improving its financial position to support ZUSDURI's market rollout and R&D activities.
- Significant Sales Growth: Total revenues reached $109.8 million in 2025, a 21% year-over-year increase driven primarily by the launch of ZUSDURI and growth in JELMYTO sales, indicating robust market performance.
- Cautious Future Outlook: While management expressed optimism about early indicators for ZUSDURI, no formal sales guidance for 2026 was provided, emphasizing the need to observe steady-state demand following the J-code implementation.
See More
UroGen (URGN) Q4 2025 Earnings Call Transcript
See More
UroGen Pharma Reports Strong Q1 2026 Earnings with Significant ZUSDURI Growth
- ZUSDURI Revenue Surge: UroGen Pharma reported $29.2 million in ZUSDURI revenue for Q1 2026, representing over 100% quarter-over-quarter growth, indicating a significant increase in market acceptance and suggesting substantial future sales potential.
- Increase in Prescribers: By the end of Q1, UroGen had 256 unique prescribers, up from 102 at year-end, with repeat prescribers rising from 32 to 103, demonstrating accelerated market penetration and growing physician engagement.
- Improved Financial Performance: The company achieved total revenue of $51 million in Q1, a substantial increase from $20.3 million in the same quarter of 2025, although it reported a net loss of $23.6 million, which is an improvement from a loss of $43.8 million a year earlier, indicating a gradual financial recovery.
- Optimistic Future Outlook: Management expects continued strong growth throughout 2026, although formal sales guidance for ZUSDURI is not provided; however, net product revenues for JELMYTO are projected to be between $97 million and $101 million, reflecting confidence in the product line.
See More
UroGen Pharma Q1 Earnings Beat Expectations
- Earnings Highlights: UroGen Pharma reported a Q1 GAAP EPS of -$0.47, beating expectations by $0.01, indicating a slight improvement in financial performance despite ongoing losses.
- Revenue Surge: The company achieved Q1 revenue of $51 million, reflecting a remarkable 151.2% year-over-year increase, surpassing estimates by $6.18 million, which underscores strong market demand for its products.
- Future Guidance: UroGen expects net product revenue for JELMYTO in 2026 to range between $97 million and $101 million, implying a year-over-year growth rate of approximately 3% to 7% over the $94 million reported in 2025, indicating a stable market outlook.
- Expense Projections: The company anticipates full-year 2026 operating expenses to be between $240 million and $250 million, including non-cash share-based compensation expenses of $20 million to $24 million, highlighting the cost pressures associated with business expansion.
See More
UroGen Pharma to Announce Q1 Earnings on May 6
- Earnings Announcement Timing: UroGen Pharma is set to release its Q1 2023 earnings report on May 6 before the market opens, with investors keenly awaiting performance insights to gauge future growth potential.
- Profit and Revenue Expectations: The consensus EPS estimate stands at -$0.48, reflecting a 47.8% year-over-year increase, while the revenue estimate is $44.82 million, indicating a substantial 120.8% year-over-year growth, showcasing strong momentum in revenue generation.
- Performance Beat Record: Over the past year, UroGen has only beaten EPS and revenue estimates 25% of the time, indicating significant volatility in its performance, which investors should closely monitor in upcoming results.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen three upward revisions and four downward adjustments, while revenue estimates have experienced two upward and five downward revisions, highlighting market uncertainty and differing expectations regarding the company's future performance.
See More
UroGen Pharma Reports 2025 Financial Highlights
- Significant Revenue Growth: UroGen Pharma reported fourth-quarter 2025 revenue of $37.8 million, a 53.3% increase from $24.6 million in the same quarter of 2024, indicating strong market demand following the launch of new products and enhancing future revenue expectations.
- Narrowed Net Loss: The net loss for the fourth quarter of 2025 was $26.4 million, or $0.54 per share, significantly improved from a net loss of $37.5 million, or $0.80 per share in the same quarter of 2024, reflecting effective cost control and revenue growth.
- Successful Launch of ZUSDURI: ZUSDURI, the first FDA-approved therapy for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, generated $15.8 million in net sales during 2025, with expectations for broader patient access supported by a permanent J Code effective January 1, 2026.
- Refinancing Agreement Restructured: UroGen secured up to $250 million in senior secured debt through a refinancing agreement with Pharmakon Advisors, with the first tranche of $200 million used to refinance an existing loan, alleviating financial pressure and providing funding for future R&D.
See More
UroGen Pharma Q4 2025 Earnings Call Highlights
- ZUSDURI Commercial Launch: UroGen Pharma's ZUSDURI generated $15.8 million in revenue for 2025, reflecting a strong market entry in non-muscle invasive bladder cancer, with potential peak revenue exceeding $1 billion anticipated in the future.
- Enhanced Financial Flexibility: The company secured a new $250 million loan agreement with Pharmakon Advisors, significantly improving its financial position to support ZUSDURI's market rollout and R&D activities.
- Significant Sales Growth: Total revenues reached $109.8 million in 2025, a 21% year-over-year increase driven primarily by the launch of ZUSDURI and growth in JELMYTO sales, indicating robust market performance.
- Cautious Future Outlook: While management expressed optimism about early indicators for ZUSDURI, no formal sales guidance for 2026 was provided, emphasizing the need to observe steady-state demand following the J-code implementation.
See More
UroGen (URGN) Q4 2025 Earnings Call Transcript
See More
